Relationship between the Tokyo Guidelines and Pathological Severity in Acute Cholecystitis
Abstract
:1. Introduction
2. Methods
2.1. Patients
2.2. Definition
2.3. Study Outcome
2.4. Statistical Analysis
3. Results
4. Discussion
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
Abbreviations
References
- Friedman, G.D. Natural history of asymptomatic and symptomatic gallstones. Am. J. Surg. 1993, 165, 399–404. [Google Scholar] [CrossRef] [PubMed]
- Yokoe, M.; Hata, J.; Takada, T.; Strasberg, S.M.; Asbun, H.J.; Wakabayashi, G.; Kozaka, K.; Endo, I.; Deziel, D.J.; Miura, F.; et al. Tokyo Guidelines 2018: Diagnostic criteria and severity grading of acute cholecystitis (with videos). J. Hepatobiliary Pancreat. Sci. 2018, 25, 41–54. [Google Scholar] [CrossRef] [PubMed]
- Blohm, M.; Österberg, J.; Sandblom, G.; Lundell, L.; Hedberg, M.; Enochsson, L. The Sooner, the Better? The Importance of Optimal Timing of Cholecystectomy in Acute Cholecystitis: Data from the National Swedish Registry for Gallstone Surgery, GallRiks. J. Gastrointest. Surg. 2017, 21, 33–40. [Google Scholar] [CrossRef] [PubMed]
- Adachi, T.; Eguchi, S.; Muto, Y. Pathophysiology and pathology of acute cholecystitis: A secondary publication of the Japanese version from 1992. J. Hepatobiliary Pancreat. Sci. 2021, 29, 212–216. [Google Scholar] [CrossRef] [PubMed]
- Takada, T.; Kawarada, Y.; Nimura, Y.; Yoshida, M.; Mayumi, T.; Sekimoto, M.; Miura, F.; Wada, K.; Hirota, M.; Yamashita, Y.; et al. Background: Tokyo Guidelines for the management of acute cholangitis and cholecystitis. J. Hepatobiliary Pancreat. Surg. 2007, 14, 1–10. [Google Scholar] [CrossRef] [PubMed]
- Yokoe, M.; Takada, T.; Strasberg, S.M.; Solomkin, J.S.; Mayumi, T.; Gomi, H.; Pitt, H.A.; Garden, O.J.; Kiriyama, S.; Hata, J.; et al. TG13 diagnostic criteria and severity grading of acute cholecystitis (with videos). J. Hepatobiliary Pancreat. Sci. 2013, 20, 35–46. [Google Scholar] [CrossRef] [PubMed]
- Barcia, J.J. Histologic analysis of chronic inflammatory patterns in the gallbladder: Diagnostic criteria for reporting cholecystitis. Ann. Diagn. Pathol. 2003, 7, 147–153. [Google Scholar] [CrossRef] [PubMed]
- Laurila, J.J.; I Ala-Kokko, T.; A Laurila, P.; Saarnio, J.; Koivukangas, V.; Syrjala, H.; Karttunen, T.J. Histopathology of acute acalculous cholecystitis in critically ill patients. Histopathology 2005, 47, 485–492. [Google Scholar] [CrossRef] [PubMed]
- Bjorvatn, B. Cholecystitis--etiology and treatment--microbiological aspects. Scand. J. Gastroenterol. Suppl. 1984, 90, 65–70. [Google Scholar] [PubMed]
- Kimura, Y.; Takada, T.; Kawarada, Y.; Nimura, Y.; Hirata, K.; Sekimoto, M.; Yoshida, M.; Mayumi, T.; Wada, K.; Miura, F.; et al. Definitions, pathophysiology, and epidemiology of acute cholangitis and cholecystitis: Tokyo Guidelines. J. Hepatobiliary Pancreat. Surg. 2007, 14, 15–26. [Google Scholar] [CrossRef] [PubMed]
- Mayumi, T.; Takada, T.; Kawarada, Y.; Nimura, Y.; Yoshida, M.; Sekimoto, M.; Miura, F.; Wada, K.; Hirota, M.; Yamashita, Y.; et al. Results of the Tokyo Consensus Meeting Tokyo Guidelines. J. Hepatobiliary Pancreat. Surg. 2007, 14, 114–121. [Google Scholar] [CrossRef] [PubMed]
- Takada, T.; Strasberg, S.M.; Solomkin, J.S.; Pitt, H.A.; Gomi, H.; Yoshida, M.; Mayumi, T.; Miura, F.; Gouma, D.J.; Garden, O.J.; et al. TG13: Updated Tokyo Guidelines for the management of acute cholangitis and cholecystitis. J. Hepatobiliary Pancreat. Sci. 2013, 20, 1–7. [Google Scholar] [CrossRef] [PubMed]
- Donohue, S.J.; Reinke, C.E.; Evans, S.L.; Jordan, M.M.; Warren, Y.E.; Hetherington, T.; Kowalkowski, M.; May, A.K.; Matthews, B.D.; Ross, S.W. Laparoscopy is associated with decreased all-cause mortality in patients undergoing emergency general surgery procedures in a regional health system. Surg. Endosc. 2022, 36, 3822–3832. [Google Scholar] [CrossRef] [PubMed]
- Cook, M.D.; Karim, S.A.; Jensen, H.K.; Bennett, J.L.; Burdine, L.J.; Bhavaraju, A.; Sexton, K.W.; Kalkwarf, K.J. Percutaneous Cholecystostomy Tubes versus Medical Management for Acute Cholecystitis. Am. Surg. 2022, 88, 828–833. [Google Scholar] [CrossRef] [PubMed]
Grade I (n = 146) | Grade II (n = 51) | Grade III (n = 20) | p-Value | |
---|---|---|---|---|
Age, years, mean ± SD | 56.9 ± 13.9 | 64.3 ± 15.4 * | 69.9 ± 9.9 * | <0.001 |
Sex, male:female | 55:91 | 25:26 | 17:3 * | <0.001 |
CRP, mg/dL | 2.95 (1.13–12.53) | 12.50 (1.90–128.90) * | 230.10 (97.88–289.88) *† | <0.001 |
WBC, /mm3 | 7495 (5990.0–9927.5) | 14,090.0 (9800.0–18,240.0) * | 14,865.0 (10,050.0–19,475.0) * | <0.001 |
PLT, /mm3 | 227,000 (190,000–268,000) | 236,000 (209,000–272,000) | 131,500 (88,000–213,750) *† | <0.001 |
Cr, mg/dL | 0.72 (0.62–0.84) | 0.81 (0.69–0.95) * | 0.99 (0.84–1.24) * | <0.001 |
Albumin, mg/dL | 4.30 (4.10–4.50) | 4.20 (3.80–4.40) * | 3.70 (3.35–3.95) *† | <0.001 |
Bilirubin, mg/dL | 0.70 (0.50–1.20) | 0.80 (0.50–1.30) | 1.60 (0.80–3.10) *† | <0.001 |
AST, IU/L | 29.0 (21.0–52.5) | 30.0 (21.0–42.0) | 89.0 (29.3–151.8) *† | 0.032 |
ALT, IU/L | 27.5 (15.0–56.5) | 24.0 (16.0–45.0) | 54.5 (18.5–93.8) | 0.257 |
ALP, IU/L | 77.0 (63.8–98.5) | 79.0 (65.0–113.0) | 81.0 (71.3–145.8) | 0.0220 |
Amylase, IU/L | 50.0 (40.8–61.0) | 31.0 (25.0–53.0) * | 3.0 (21.3–35.0) * | <0.001 |
Lipase, IU/L | 18.0 (12.0–26.0) | 12.0 (7.0–22.0) * | 12.5 (6.5–16.0) * | <0.001 |
PT-INR | 1.06 (1.01–1.10) | 1.14 (1.07–1.22) * | 1.28 (1.18–1.48) *† | <0.001 |
Grade I (n = 146) | Grade II (n = 51) | Grade III (n = 20) | Total (n = 217) | p-Value | |
---|---|---|---|---|---|
Blood | 0 (0/146) | * 2.0% (1/51) | ** 20% (4/20) | 2.3 (5/217) | <0.001 |
Bile | † 19.9% (29/146) | †† 33.3% (17/51) | ††† 70% (14/20) | 27.6% (60/217) | <0.001 |
Grade I (n = 146) | Grade II (n = 51) | Grade III (n = 20) | p-Value | |
---|---|---|---|---|
Eosinophils | 1.0 (0.0–1.0) | 1.0 (0.0–2.0) | 0.0 (0.0–1.0) | 0.211 |
Neutrophils | 0.0 (0.0–1.0) | 0.0 (0.0–2.0) | 0.5 (0.0–2.0) | <0.001 |
Lymphocytes | 1.0 (1.0–2.0) | 2.0 (1.0–2.0) | 1.0 (1.0–2.0) | 0.522 |
Adenomyoma | 0.0 (0.0–0.0) | 0.0 (0.0–0.0) | 0.0 (0.0–0.0) | 0.270 |
Cholesterolosis | 13 (9.1%) | 1 (2.0%) | 0 (0.0%) | 0.101 |
Grade I (n = 123) | Grade II (n = 40) | Grade III (n = 15) | p-Value | |
---|---|---|---|---|
84.2% (123/146) | 78.4% (40/51) | 75% (15/20) | 0.010 | |
Calcium bilirubinate | 40.7% (50/123) | 70.0% (28/40) | 80% (12/15) | |
Cholesterol | 48.0% (59/123) | 22.5% (9/40) | 13.3% (2/15) | |
Mixed | 9.8% (12/123) | 7.5% (3/40) | 6.7% (1/15) | |
Protein stones | 1.6% (2/123) | 0 | 0 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Park, T.Y.; Do, J.H.; Oh, H.-C.; Choi, Y.S.; Lee, S.E.; Kang, H.; Hong, S.A. Relationship between the Tokyo Guidelines and Pathological Severity in Acute Cholecystitis. J. Pers. Med. 2023, 13, 1335. https://doi.org/10.3390/jpm13091335
Park TY, Do JH, Oh H-C, Choi YS, Lee SE, Kang H, Hong SA. Relationship between the Tokyo Guidelines and Pathological Severity in Acute Cholecystitis. Journal of Personalized Medicine. 2023; 13(9):1335. https://doi.org/10.3390/jpm13091335
Chicago/Turabian StylePark, Tae Young, Jae Hyuk Do, Hyoung-Chul Oh, Yoo Shin Choi, Seung Eun Lee, Hyun Kang, and Soon Auck Hong. 2023. "Relationship between the Tokyo Guidelines and Pathological Severity in Acute Cholecystitis" Journal of Personalized Medicine 13, no. 9: 1335. https://doi.org/10.3390/jpm13091335
APA StylePark, T. Y., Do, J. H., Oh, H.-C., Choi, Y. S., Lee, S. E., Kang, H., & Hong, S. A. (2023). Relationship between the Tokyo Guidelines and Pathological Severity in Acute Cholecystitis. Journal of Personalized Medicine, 13(9), 1335. https://doi.org/10.3390/jpm13091335